Evidence map›Paper›PMID 39536799›Full record

ArticleInternational journal of radiation oncology, biology, physics2025

Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity-Modulated Radiation Therapy.

Diana A Roth O'Brien, Vasilis C Hristidis, Zakaria Chakrani, Patrick McCann, Antonio Damato, Vonetta Williams, Nicolas Cote, Marsha Reyngold, Roni Rosen, Louise Connell and 22 more

Abstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Diana A Roth O'BrienDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Vasilis C HristidisDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Zakaria ChakraniDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Patrick McCannDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Antonio DamatoDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Vonetta WilliamsDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Nicolas CoteDepartment of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.
Marsha ReyngoldDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Roni RosenDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Louise ConnellDepartment of Medicine, Gastrointestinal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Emmanouil PappouDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Carla HajjDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Philip B PatyDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Natally HorvatDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jennifer S Golia PernickaDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Megan FiasconaroDepartment of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Jinru ShiaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Jeanine LisantiDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Abraham J WuDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Marc J GollubDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Zhigang ZhangDepartment of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Rona YaegerDepartment of Medicine, Gastrointestinal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Melissa ZinovoyDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Martin R WeiserDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Len SaltzDepartment of Medicine, Gastrointestinal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
John CuaronDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Lillian BoeDepartment of Epidemiology and Biostatistics, Biostatistics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Andrea CercekDepartment of Medicine, Gastrointestinal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Julio Garcia-AguilarDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
J Joshua SmithDepartment of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Christopher H CraneDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Paul B RomesserDepartment of Radiation Oncology, Colorectal and Anal Cancer Service, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: romessep@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Investigating the contribution of cellular senescence to the efficacy of radiation therapy.K08CA255574 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROMESSER, PAUL BERNARD · 2021 to 2025
$1.2M
NCI NIH HHS K08 CA255574NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposePatterns of failure and salvage therapy options for patients with anal squamous cell carcinoma (ASCC) who recur after definitive-intent intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy are not well described. METHODS AND MATERIALS: We identified consecutive patients with ASCC treated with definitive-intent IMRT between July 2005 and December 2019. Relevant patient and tumor parameters, disease outcomes (locoregional failure [LRF], distant failure, progression-free survival, colostomy-free survival, and overall survival [OS]), patterns of failure, and salvage therapies were collected. Failures were analyzed using competing risk methods, whereas survival endpoints were estimated using the Kaplan-Meier method. Univariate and multivariate analyses were performed. Landmark analyses were conducted by considering whether patients had LRF within 12 months of completing IMRT.

resultsA total of 375 patients were identified with a median follow-up of 6 years. Stage breakdown was 15%, 23%, and 62% for the American Joint Committee on Cancer stages 0 to I, II, and III, respectively. Six-year rates of LRF, distant failure, progression-free survival, colostomy-free survival, and OS were 12%, 13%, 73%, 76%, and 80%, respectively. Disease recurred in 74 patients. Among the 45 patients with LRF, 39 (87%) failed within the anorectum, with 25 anal canal, 6 anal margin, and 8 rectal recurrences. Only 4 (9%) patients had isolated nodal failure. Patients experiencing LRF had worse 6-year OS than patients without LRF (44% vs 86%, P < .0001). Approximately 30% of patients who underwent salvage therapy were alive to 10 years after recurrence, compared with none of the patients who were managed with chemotherapy alone or the best supportive care.

conclusionsThis large ASCC cohort managed with definitive-intent IMRT demonstrated excellent rates of locoregional control and survival. Isolated regional nodal failures were uncommon, whereas the majority of LRFs occurred within the anorectum, despite dose escalation by tumor stage. We observed poor outcomes for patients experiencing locoregional disease recurrence, even after aggressive salvage treatment.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellRadiotherapy, Intensity-ModulatedSalvage TherapyAdultAgedAged, 80 and overChemoradiotherapyColostomyFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalRetrospective Studies

Identifiers

PMID39536799
PMCPMC12067387

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.